Related Experiment Video
Updated: Mar 14, 2026
06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
1.3K
Mutant IDH1 and thrombosis in gliomas
Dusten Unruh1, Steven R Schwarze2, Laith Khoury3
1Department of Neurosurgery, Northwestern University, Tarry 2-705, 300 East Superior Street, Chicago, IL, 60611, USA.
Acta Neuropathologica
|September 25, 2016
Summary
Mutant isocitrate dehydrogenase 1 (IDH1) in gliomas inhibits blood clotting and reduces microthrombi formation. This finding reveals IDH1 mutations as a potent antithrombotic marker in glioma patients, impacting VTE risk assessment.
Area of Science:
- Oncology
- Hematology
- Molecular Biology
Background:
- Mutant isocitrate dehydrogenase 1 (IDH1) is prevalent in gliomas, producing D-2-hydroxyglutarate (D-2-HG).
- The impact of IDH1 mutations on glioma biology and the tumor microenvironment remains incompletely understood.
- Venous thromboembolism (VTE) is a significant concern in glioma patients.
Purpose of the Study:
- To investigate the effects of IDH1 mutations on glioma-associated microthrombi and VTE.
- To explore the antithrombotic mechanisms associated with mutant IDH1 and D-2-HG.
- To assess the predictive value of IDH1 mutation status for VTE risk in glioma patients.
Main Methods:
- Analysis of IDH1 mutations, microthrombi, and VTE in discovery and validation glioma cohorts.
- Genomic analysis of coagulation-associated genes and tissue factor (TF) protein expression in gliomas.
- In vitro and in vivo assays to evaluate the impact of mutant IDH1 and D-2-HG on platelet aggregation and clotting time.
Main Results:
- VTE occurred in 0% of patients with mutant IDH1 gliomas versus 26-30% in wild-type IDH1 gliomas.
- Microthrombi were significantly less common in mutant IDH1 gliomas (2-6%) compared to wild-type (85-90%).
- Mutant IDH1 and D-2-HG demonstrated potent antithrombotic activity by inhibiting platelet aggregation and prolonging clotting time.
Conclusions:
- Mutant IDH1 possesses significant antithrombotic properties, reducing VTE and microthrombi formation in gliomas.
- IDH1 mutation status is a powerful independent predictor of VTE risk in glioma patients.
- These findings have implications for glioma pathology, tumor microenvironment understanding, and VTE risk stratification.
